Get started
Author

Asit Parikh

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 · Brian G. Feagan, Paul Rutgeerts, et al. · New England Journal of Medicine · 2,893
PDF
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 · William J. Sandborn, Brian G. Feagan, et al. · New England Journal of Medicine · 2,720
PDF
The safety of vedolizumab for ulcerative colitis and Crohn's disease
2016 · Jean-Frédéric Colombel, Bruce E Sands, et al. · Gut · 807
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
2014 · Bruce E. Sands, Brian G. Feagan, et al. · Gastroenterology · 715
PDF
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
2008 · Brian G. Feagan, Gordon R. Greenberg, et al. · Clinical Gastroenterology and Hepatology · 285
Drug metabolism by Escherichia coli expressing human cytochromes P450
1997 · Asit Parikh, Elizabeth M.J. Gillam, et al. · Nature Biotechnology · 285
Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
2011 · Asit Parikh, Timothy Leach, et al. · Inflammatory Bowel Diseases · 210
PDF
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
2014 · Tim Wyant, Tim Leach, et al. · Gut · 177
Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease
2017 · Maria Rosario, Jonathan L French, et al. · Journal of Crohn s and Colitis · 164
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
2017 · Maria Rosario, Nathanael L. Dirks, et al. · Clinical Pharmacokinetics · 158
PDF
Corrigendum: Exposure—efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease
2018 · Maria Rosario, Jonathan L French, et al. · Journal of Crohn s and Colitis · 123
PDF
Selection and Characterization of Human Cytochrome P450 1A2 Mutants with Altered Catalytic Properties
1999 · Asit Parikh, P. David Josephy, et al. · Biochemistry · 99
Metabolic Activation of Aromatic Amine Mutagens by Simultaneous Expression of Human Cytochrome P450 1A2, NADPH-Cytochrome P450 Reductase, and N-Acetyltransferase in Escherichia coli
1998 · P. David Josephy, David H. Evans, et al. · Chemical Research in Toxicology · 81
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
2013 · Asit Parikh, Irving Fox, et al. · Inflammatory Bowel Diseases · 80
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
2013 · Catherine Milch, Tim Wyant, et al. · Journal of Neuroimmunology · 78
Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype
1999 · F.Peter Guengerich, Asit Parikh, et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 65
Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts.
2001 · J Pinski, A Parikh, et al. · PubMed · 58
Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
2014 · Jonathan Goldman, S. Gail Eckhardt, et al. · Clinical Cancer Research · 48
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
2016 · Maria Rosario, Timothy Wyant, et al. · Clinical Drug Investigation · 44
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database
2015 · Megan E. McAuliffe, Stephan Lanes, et al. · Current Medical Research and Opinion · 42
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
2018 · Walter Reinisch, Brian Bressler, et al. · Inflammatory Bowel Diseases · 40
Expression, Purification, and Characterization of a Catalytically Active Human Cytochrome P450 1A2:Rat NADPH-Cytochrome P450 Reductase Fusion Protein
1997 · Asit Parikh, F.Peter Guengerich · Protein Expression and Purification · 33
Random Mutagenesis by Whole-Plasmid PCR Amplification
1998 · Asit Parikh, F. Peter Guengerich · BioTechniques · 32
Expression of drug-metabolizing enzymes
1997 · F Peter Guengerich, Asit Parikh · Current Opinion in Biotechnology · 30
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
2020 · Maria T. Abreu, William J. Sandborn, et al. · Gastroenterology · 29
Works count: 56
Citation count: 9,466
H-index: 25
I10-index: 31
Year
Topic
Type